A new type of nanoparticle that can be absorbed through the digestive tract would allow patients to take pills instead of receiving injections for the treatment of several common diseases and could potentially improve therapy compliance, suggests new research.
A new study from researchers at Yale University has found that a single dose of intranasal oxytocin impacts brain activity in children with autism spectrum disorder (ASD).
Adding the histone deacetylase inhibitor vorinostat (Zolinza) to standard immunoprophylaxis against acute graft-versus-host disease (GVHD) during bone marrow transplant reduced the overall rate of the complication, said a recent study.
Novo Nordisk received European Union marketing authorization for its recombinant coagulation factor VIII drug NovoEight (turoctocog alfa) in November, the Danish pharmaceutical company said on Monday.
Individuals who take formulations of drugs containing sodium have a significantly increased risk of suffering adverse cardiovascular events compared with those who take standard formulations of the same drugs, according to a new study.
British drugmaker Shire's dry eye drug lifitegrast reduced patient-reported symptoms of eye dryness in a late-stage trial - the first drug to do so in a phase III setting - but it missed a second target that measured signs of the disease based on corneal staining.
Measuring how quickly nanoparticles are cleared from the body helps determine the proper dosage of nanoparticle-based drugs administered to cancer patients, according to investigators at the University of North Carolina.
In the wake of the Patient Protection and Affordable Care Act (ACA), the Kaiser Foundation conducted a tracking poll to determine the public’s view of the law.
Genetic testing is underutilized during the prescribing of antiplatelet therapy, likely because of physician uncertainty regarding the rapidly evolving evidence for pharmacogenomics.